Valneva SE (LON:0OB3)
3.498
-0.009 (-0.26%)
Dec 19, 2025, 5:13 PM BST
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M EUR
Revenue Growth
+13.48%
P/S Ratio
3.41
Revenue / Employee
252.33K EUR
Employees
713
Market Cap
536.25M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Valneva SE News
- 10 days ago - Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine - GuruFocus
- 10 days ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 15 days ago - VALNEVA Declaration of shares and voting rights: November 30, 2025 - GlobeNewsWire
- 24 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 24 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 24 days ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 24 days ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ
- 24 days ago - Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety - Nasdaq